The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials - PubMed

The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials

Souraya Ramjanee et al. Vaccine. 2007.

Abstract

P25 is a major surface protein of Plasmodium ookinetes. Antibodies against P25 prevent the formation of oocysts in the mosquito and thereby block transmission of the parasite through an endemic population. Plasmodium vivax transmission-blocking vaccines based on Pv25 have undergone human trials and inhibit transmission significantly. The current assay to determine transmission-blocking activity (TBA) of these sera, the 'standard membrane feeding assay', is complex and can be performed by few groups worldwide that require both mosquito breeding facilities and access to volunteers naturally infected with P.vivax--a costly, and uncontrolled source of parasites. Here we report the development of novel assays to determine TBA using two clones (Pv25DR and Pv25DR3) of transgenic rodent parasites (Plasmodium berghei) expressing Pv25. We show that oocyst development of the transgenic parasites is inhibited by monoclonal antibody against Pv25 with the same kinetics exhibited by wild type parasites when exposed to mouse monoclonal antibodies targeted to a paralogous protein P28. Human transmission-blocking sera from a clinical vaccine trial of Pv25 inhibited oocyst development of Pv25DR and Pv25DR3, whereas non-blocking sera did not. We further show transmission-blocking activity can be determined in a simple assays of ookinete development in vitro, assays that obviate the need for mosquito colonies. These results demonstrate that transgenic rodent malarias expressing proteins from human Plasmodium species can be cheap, safe, and simple tools for testing TBA from sera. To this end the cloned lines have been deposited with, and are freely available from, MR4.

Similar articles

• Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro.

  Blagborough AM, Sinden RE. Blagborough AM, et al. Vaccine. 2009 Aug 20;27(38):5187-94. doi: 10.1016/j.vaccine.2009.06.069. Epub 2009 Jul 9. Vaccine. 2009. PMID: 19596419 Review.

• Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.

  Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A. Miura K, et al. Malar J. 2007 Aug 8;6:107. doi: 10.1186/1475-2875-6-107. Malar J. 2007. PMID: 17686163 Free PMC article.

• Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.

  Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N, Rungruang T, Cao YM, Stowers AW, Sirichaisinthop J, Coleman RE, Torii M. Sattabongkot J, et al. Am J Trop Med Hyg. 2003 Nov;69(5):536-41. Am J Trop Med Hyg. 2003. PMID: 14695092

• Evaluation of the transmission-blocking potential of Plasmodium vivax antigen Pvg37 using transgenic rodent parasites and clinical isolates.

  Zhang D, Zhao Y, Liu D, Liu F, Liu P, Zhang B, Wu Z, Roobsoong W, Bantuchai S, Thongpoon S, Sripoorote P, Wang M, Cui L, Cao Y. Zhang D, et al. Front Cell Infect Microbiol. 2025 Jan 24;15:1529770. doi: 10.3389/fcimb.2025.1529770. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 39925376 Free PMC article.

• Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?

  Baton LA, Ranford-Cartwright LC. Baton LA, et al. Malar J. 2005 Feb 25;4:15. doi: 10.1186/1475-2875-4-15. Malar J. 2005. PMID: 15733320 Free PMC article. Review.

Cited by

• Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone.

  McCoy KD, Weldon CT, Ansumana R, Lamin JM, Stenger DA, Ryan SJ, Bardosh K, Jacobsen KH, Dinglasan RR. McCoy KD, et al. Malar J. 2021 Apr 13;20(1):183. doi: 10.1186/s12936-021-03723-0. Malar J. 2021. PMID: 33849572 Free PMC article.

• A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.

  Goodman AL, Blagborough AM, Biswas S, Wu Y, Hill AV, Sinden RE, Draper SJ. Goodman AL, et al. PLoS One. 2011;6(12):e29428. doi: 10.1371/journal.pone.0029428. Epub 2011 Dec 28. PLoS One. 2011. PMID: 22216279 Free PMC article.

• Evaluation of transmission-blocking potential of Pv22 using clinical Plasmodium vivax infections and transgenic Plasmodium berghei.

  Bai J, Liu F, Yang F, Zhao Y, Jia X, Thongpoon S, Roobsoog W, Sattabongkot J, Zheng L, Cui Z, Zheng W, Cui L, Cao Y. Bai J, et al. Vaccine. 2023 Jan 9;41(2):555-563. doi: 10.1016/j.vaccine.2022.11.058. Epub 2022 Dec 8. Vaccine. 2023. PMID: 36503858 Free PMC article.

• Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.

  Mlambo G, Maciel J, Kumar N. Mlambo G, et al. Infect Immun. 2008 May;76(5):2018-24. doi: 10.1128/IAI.01409-07. Epub 2008 Mar 3. Infect Immun. 2008. PMID: 18316385 Free PMC article.

• Functional Conservation of P48/45 Proteins in the Transmission Stages of Plasmodium vivax (Human Malaria Parasite) and P. berghei (Murine Malaria Parasite).

  Cao Y, Hart RJ, Bansal GP, Kumar N. Cao Y, et al. mBio. 2018 Sep 4;9(5):e01627-18. doi: 10.1128/mBio.01627-18. mBio. 2018. PMID: 30181253 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science